BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nascimento FP, Macedo-Júnior SJ, Lapa-Costa FR, Cezar-Dos-Santos F, Santos ARS. Inosine as a Tool to Understand and Treat Central Nervous System Disorders: A Neglected Actor? Front Neurosci 2021;15:703783. [PMID: 34504414 DOI: 10.3389/fnins.2021.703783] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Kim IS, Jo E. Inosine: A bioactive metabolite with multimodal actions in human diseases. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1043970] [Reference Citation Analysis]
2 Carneiro TJ, Vojtek M, Gonçalves-monteiro S, Batista de Carvalho ALM, Marques MPM, Diniz C, Gil AM. Effect of Pd2Spermine on Mice Brain-Liver Axis Metabolism Assessed by NMR Metabolomics. IJMS 2022;23:13773. [DOI: 10.3390/ijms232213773] [Reference Citation Analysis]
3 Zhao YF, Verkhratsky A, Tang Y, Illes P. Astrocytes and major depression: The purinergic avenue. Neuropharmacology 2022;220:109252. [PMID: 36122663 DOI: 10.1016/j.neuropharm.2022.109252] [Reference Citation Analysis]
4 Ahuja M, Kaidery NA, Dutta D, Attucks OC, Kazakov EH, Gazaryan I, Matsumoto M, Igarashi K, Sharma SM, Thomas B. Harnessing the Therapeutic Potential of the Nrf2/Bach1 Signaling Pathway in Parkinson's Disease. Antioxidants (Basel) 2022;11:1780. [PMID: 36139853 DOI: 10.3390/antiox11091780] [Reference Citation Analysis]
5 Cai H, Zeng C, Zhang X, Liu Y, Wu R, Guo W, Wang J, Wu H, Tang H, Ge X, Yu Y, Zhang S, Cao T, Li N, Liang X, Yang P, Zhang B. Diminished treatment response in relapsed versus first-episode schizophrenia as revealed by a panel of blood-based biomarkers: A combined cross-sectional and longitudinal study. Psychiatry Res 2022;316:114762. [PMID: 35940088 DOI: 10.1016/j.psychres.2022.114762] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Basile MS, Bramanti P, Mazzon E. Inosine in Neurodegenerative Diseases: From the Bench to the Bedside. Molecules 2022;27:4644. [DOI: 10.3390/molecules27144644] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Gonçalves MCB, Andrejew R, Gubert C. The Purinergic System as a Target for the Development of Treatments for Bipolar Disorder. CNS Drugs 2022. [PMID: 35829960 DOI: 10.1007/s40263-022-00934-0] [Reference Citation Analysis]
8 Dutta N, Deb I, Sarzynska J, Lahiri A. Inosine and its methyl derivatives: Occurrence, biogenesis, and function in RNA. Progress in Biophysics and Molecular Biology 2022;169-170:21-52. [DOI: 10.1016/j.pbiomolbio.2022.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Abdelkader NF, Ibrahim SM, Moustafa PE, Elbaset MA. Inosine mitigated diabetic peripheral neuropathy via modulating GLO1/AGEs/RAGE/NF-κB/Nrf2 and TGF-β/PKC/TRPV1 signaling pathways. Biomed Pharmacother 2021;145:112395. [PMID: 34775239 DOI: 10.1016/j.biopha.2021.112395] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]